NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NHTC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain dividend payments near $0.1 per share | A supporting condition in NATURAL HEALTH TRENDS CORP's published investment case. The stated target is Dividend per share >= $0.1 next 4 quarters. | Intact | Dividend per share falls below $0.1 next 4 quarters | Dividend per share: $0.10 per share FY2026-Q2; GAAP. Published target: Dividend per share >= $0.1 next 4 quarters. Target period is not explicitly aligned with this observation. Jul 29, 20260.1 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk restructuring story, not a proven durable compounder. The thesis is in a watch state, with a recent shift from cautious to mixed, but the underlying financial performance remains weak.
NHTC is described as cheap versus peers, while the valuation model has low confidence and the expectations gap is negative. The priced-in assessment is justified rather than showing broad, concentrated fragility, so the evidence does not establish that weak execution is fully reflected in the valuation.
Near term, earnings risk is elevated, and another guidance cut or earnings miss would add pressure to an already weak record. Restructuring narrowed the operating loss from the second to the third quarter, but the first-nine-month loss increased year over year, while third-quarter revenue fell year over year despite a rise in active members.
The multi-year view depends on whether cost reductions translate into sustained improvement in results and whether member growth can support revenue. Near term, guidance and execution are key risks; broader consumer-sector momentum may help, but could fade if major sector companies miss or lower guidance.
Over the next 1 to 3 years, NHTC remains a watch-state restructuring story with some sequential progress but weak cumulative results and high execution risk. The thesis hinges on translating cost focus and member growth into stronger business results. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Improve operating income from negative levels | Operating losses are shrinking but still negative. | Broken | Operating income remains negative through FY26 | Operating income: $-277,000 FY2026-Q3; GAAP. Published target: Operating income >= $0 by FY26. Annual target cannot be compared with a quarterly or TTM observation. Oct 28, 2026-277,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Complete share repurchase of 25.5% outstanding shares | A primary condition in NATURAL HEALTH TRENDS CORP's published investment case. The stated target is Repurchase 2,935,227 shares by 2026-Q1. | Intact | Repurchased shares fall short of 2,900,000 by 2026-Q1 | Required source inputs unavailable Cannot calculate Share repurchases from the available matching source inputs. Missing inputs are not treated as zero. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “The Company ’ s Board of Directors has since authorized additional share repurchases under its existing stock repurchase program, subject to market conditions and other relevant considerations.” “|| • | The Company's Board of Directors has authorized the resumption of share repurchases under its existing stock repurchase program, with $15.9 million remaining available, subject to market conditions and other relevant considerations.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.